ArticleScientific reports2026
The relationship between lactate-to-albumin ratio and prognosis in patients with sepsis-induced cardiomyopathy: a retrospective cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lactate-to-albumin ratio (LAR) has been reported as a prognostic marker in various diseases, but its association with outcomes in patients with sepsis-induced cardiomyopathy (SICM) remains unclear. This study aimed to evaluate the prognostic value of LAR in SICM patients. We retrospectively analyzed data from SICM patients admitted to the intensive care unit (ICU) of Beth Israel Deaconess Medical Center between 2008 and 2022. LAR was calculated using laboratory values obtained within 24 h of ICU admission. The optimal LAR cutoff was determined using R software. Survival analysis was performed with Kaplan-Meier curves, and multivariate logistic regression models were used to assess the association between LAR and 28-day mortality. Restricted cubic spline (RCS) analysis explored the dose-response relationship, and subgroup analyses evaluated consistency across populations. Among 1,810 included patients, the optimal LAR cutoff was 1.094. Kaplan-Meier analysis showed significantly higher 28-day mortality in the high-LAR group (log-rank P < 0.001). Multivariate logistic regression confirmed LAR as an independent predictor of mortality (adjusted OR = 1.42, 95% CI: 1.04-1.93). RCS revealed a non-linear relationship between LAR and mortality (P for non-linear = 0.001), and subgroup analyses showed no significant interactions. LAR is independently associated with short-term prognosis in SICM patients and may serve as a practical biomarker for risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.